| Autor: |
J Edwards, Yvonne Chen, Dheeraj Shukla, Xiao Lan, Rebecca Angus, Rumbidzai N. Mutsekwa, H Moattar, Pradeep Kakkadasam Ramaswamy |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Gastroenterology. 158:S-1210 |
| ISSN: |
0016-5085 |
| DOI: |
10.1016/s0016-5085(20)33685-4 |
| Popis: |
Background: We aimed to describe the real-world effectiveness and safety of the oral JAK inhibitor tofacitinib (tofa) in Crohn's disease (CD). Methods: We analyzed a retrospective, multi-center cohort from 3 IBD referral centers in the United States. CD pts started on tofa for active disease were included. The primary outcome was clinical response (> 50% reduction in symptoms) at week 8 determined by physician global assessment. Secondary outcomes included clinical remission at week 8. Adverse events (AEs) were recorded. Abnormal lipid.. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
